Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Invex Therapeutics Ltd. ( (AU:IXC) ) has shared an update.
Invex Therapeutics Ltd has received notices from Celtic Capital Pte Ltd, which holds more than 5% of the company’s voting shares, requesting a general meeting to consider the removal of two directors. If the notices are valid, the company must hold the meeting within two months, potentially impacting its governance and strategic direction.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company that focuses on repurposing the approved drug Exenatide for treating neurological conditions associated with raised intracranial pressure. The company has trademarked this repurposed drug as Presendin™.
Average Trading Volume: 51,105
Technical Sentiment Signal: Buy
Current Market Cap: A$7.52M
For a thorough assessment of IXC stock, go to TipRanks’ Stock Analysis page.